Syndax Pharmaceuticals, Inc. Available-for-sale Securities, Gross Realized Gain (Loss)
Syndax Pharmaceuticals, Inc. (SNDX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-08-08
- Syndax Pharmaceuticals, Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-03-31 was $0.00.
- Syndax Pharmaceuticals, Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month | Available-for-sale Securities, Gross Realized Gain (Loss) 36 month |
|---|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | ||||
| 2017-12-31 | $0.00 10-K · filed 2018-03-08 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-08-08 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 4 quarters · filed 2018-08-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $0.00 derived: sum of 3 quarters · filed 2018-08-08 | $0.00 derived: sum of 4 quarters · filed 2018-08-08 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2018-05-09 | $0.00 derived: sum of 3 quarters · filed 2018-05-09 | $0.00 derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $0.00 derived: sum of 2 quarters · filed 2017-03-14 | $0.00 derived: sum of 3 quarters · filed 2017-03-14 | $0.00 10-K · filed 2017-03-14 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-15 | $0.00 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-16 | ||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |